The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Lodha Developers Buys Solidrise for Rs 300 Cr; Shares Jump 1.5%
• Stocks Under F&O Ban: Sammaan Capital, and Others 
• Overnight Stock Market Movements: Key Developments 
• India Approves 25 LMT Wheat, 5 LMT Sugar Export Quota
• US Core Inflation Seen at 5-Year Low Ahead of Friday Report

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.